French-founded global testing, inspection and laboratory services company covering food, environment, pharma and genomics.
French-founded global testing, inspection and laboratory services company covering food, environment, pharma and genomics.
Charges per test or per project for lab analysis, often under recurring routine-testing contracts, so work is steady and tied to regulation and quality-control rules rather than customers' sales. It grew mainly by buying small labs. The Martin family, led by founder Gilles Martin, keeps control through its holding company.
Moat: narrow (scale, distribution, regulatory licence). Dense global lab network built through hundreds of acquisitions gives scale and local accreditation.
Headquarters: Luxembourg · Founded: 1987 · Employees: 65,694
Size Eurofins Scientific (ERF.PA) is a France Industrials company (Miscellaneous Commercial Services) with a market value of $16.4B, the 36th largest of 206 France companies the cockpit tracks. Shares closed at €85.06 on 18 Nov 2026.
Performance Over six months the shares gained 37.3%, against +8.5% for the median peer and -2.1% for the France market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 3.4% over the last twelve months (peer median +4.5%); the operating margin is 12.5% (peer median 15.6%).
Valuation It trades at 22.1× forward earnings against a peer median of 20.6× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points above its cost of capital (7.8% WACC).
Credit Eurofins Scientific has 6 bonds outstanding ($3.83B), rated Baa3 by the agencies and trading like BBB at a weighted spread of 108 bp.
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €7.39B | €7.30B | €6.95B | €6.51B | €6.71B |
| Revenue growth | — | +5% | +7% | -3% | — |
| Gross profit | €920M | €897M | €794M | €620M | €824M |
| EBITDA | €1.63B | €1.54B | €1.42B | €1.21B | €1.39B |
| Net income | €530M | €475M | €406M | €310M | €610M |
| Free cash flow | €634M | €534M | €770M | €469M | €513M |
| Capital expenditure | €806M | €835M | €528M | €550M | €660M |
| Total debt | n/a | €5.43B | €4.61B | €4.93B | €3.91B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Eurofins Scientific ERF.PA | $16.4B | +37% | +3% | 12% | 22.1× | 12.9% |
| Sgs SGSN.SW | $24.0B | +17% | +5% | 15% | 24.5× | 3.1% |
| Bureau Veritas BVI.PA | $14.8B | +17% | +2% | 15% | 20.6× | 8.3% |
| Intertek ITRK.L | $12.0B | +8% | +4% | 18% | 22.5× | 15.0% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ERF.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.7% | +7.8% | 10th lowest of 21 |
| 6-month return | +37.3% | +8.5% | 2nd highest of 20 |
| Distance from 52-week high | -4.7% | -14.5% | 8th highest of 21 |
| Revenue growth (TTM) | +3.4% | +4.5% | 8th lowest of 21 |
| Operating margin | 12.5% | 15.6% | 6th lowest of 21 |
| Forward P/E | 22.1× | 20.6× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 12.9% | 8.3% | 6th most demanding of 20 |
| Growth delivered (Del g) | +6.1% | +7.5% | 7th lowest of 20 |
| Hurdle (Req g minus delivered) | +6.9 pp | -3.5 pp | 3rd most demanding of 20 |
| ROIC minus cost of capital | +0.2 pp | +8.4 pp | 5th lowest of 19 |
| EV / EBITDA | 12.2× | 12.4× | 10th cheapest of 20 |
| Net debt / EBITDA | 3.0× | 1.8× | 2nd most indebted of 20 |
| Bond spread | 108 bp | 98 bp | 5th widest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eurofins Scientific ERF.PA | France | $16.4B | +37% | +3% | 12% | 22.1× | 12.9% | +6.1% |
| UL Solutions ULS | United States | $15.5B | -24% | +6% | 19% | 30.5× | 9.1% | +5.8% |
| Computershare CPU.AX | Australia | $17.7B | +37% | 0% | 30% | 19.5× | -1.7% | +9.2% |
| Rollins ROL | United States | $18.0B | -29% | +8% | 19% | 31.3× | 11.4% | +11.7% |
| Bureau Veritas BVI.PA | France | $14.8B | +17% | +2% | 15% | 20.6× | 8.3% | +7.0% |
| Secom 9735.T | Japan | $20.3B | +17% | +4% | 13% | 24.3× | 0.4% | +3.9% |
| Baycurrent 6532.T | Japan | $12.1B | +147% | +32% | 33% | 38.9× | 7.1% | +28.2% |
| Intertek ITRK.L | United Kingdom | $12.0B | +8% | +4% | 18% | 22.5× | 15.0% | +4.6% |
| Rentokil Initial RTO.L | United Kingdom | $11.8B | -23% | 0% | 14% | 16.8× | 8.7% | +13.4% |
| Sgs SGSN.SW | Switzerland | $24.0B | +17% | +5% | 15% | 24.5× | 3.1% | +4.4% |
| Booz Allen Hamilton BAH | United States | $9.97B | +9% | -6% | 9% | 13.1× | -6.8% | +7.4% |
| CETC Lantian Technology 688818.SS | China | $9.69B | -52% | +5% | 9% | 172.0× | n/a | n/a |
| Adyen ADYEN.AS | Netherlands | $29.1B | -14% | +17% | 42% | 22.0× | 16.6% | -6.0% |
| Securitas SECU-B.ST | Sweden | $9.03B | 0% | -5% | 7% | 12.5× | -4.5% | +7.5% |
| CAE CAE.TO | Canada | $8.84B | +8% | +3% | 13% | 29.9× | 13.7% | +10.5% |
| Spie SPIE.PA | France | $8.58B | -8% | +3% | 6% | 14.8× | 9.1% | +9.3% |
| Experian EXPN.L | United Kingdom | $33.0B | +11% | +7% | 25% | 18.7× | 13.7% | +8.9% |
| Airtel Mobile Commerce AMC.L | United Kingdom | $8.02B | n/a | +30% | 48% | n/a | 16.2% | +30.3% |
| Universal Music UMG.AS | Netherlands | $34.8B | -15% | +5% | 16% | 17.6× | 7.4% | +11.0% |
| Iss A/s ISS.CO | Denmark | $7.34B | +19% | +4% | 5% | 16.3× | -5.7% | +3.7% |
| Genpact G | United States | $7.02B | +31% | +7% | 16% | 9.5× | -7.0% | +6.5% |
Eurofins Scientific has 6 bonds outstanding with $3.83B face value. The agencies rate it Baa3; its bonds trade like BBB. Weighted yield 4.18%, a spread of 108 bp over government bonds.